Low-Dose Metformin Treatment Reduces In Vitro Growth of the LL/2 Non-small Cell Lung Cancer Cell Line

Lung cancer maintains a relatively small survival rate (~19%) over a 5-year period and up to 80–85% of all lung cancer diagnoses are Non-Small Cell Lung Cancer (NSCLC). To determine whether metformin reduces non-small cell lung cancer (NSCLC) LL/2 cell growth, cells were grown in vitro and treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, Nicole L. Stott, Dréau, Didier, Marriott, Ian, Bennett, Jeanette M., Turner, Michael J., Arthur, Susan T., Marino, Joseph S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856116/
https://www.ncbi.nlm.nih.gov/pubmed/36672573
http://dx.doi.org/10.3390/biomedicines11010065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856116/
https://www.ncbi.nlm.nih.gov/pubmed/36672573
http://dx.doi.org/10.3390/biomedicines11010065

Ejemplares similares